Literature DB >> 28990646

[Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in Internal Medicine and Neurology departments of Spain].

G Reig-Rosello1, M M Contreras1, C Suarez-Fernandez1, A Gonzalez-Hernandez2, P Cardona3, J M Pons-Amate4, J Marti-Fabregas5, J Vivancos1.   

Abstract

AIM: To determine the clinical profile, management of anticoagulant treatment and satisfaction related to anticoagulation in outpatients with nonvalvular atrial fibrillation attended in Neurology or Internal Medicine departments of Spain. PATIENTS AND METHODS: Cross-sectional and multicenter study, in which 1,337 outpatients were included. Patients fulfilled ACTS, SAT-Q and EQ-5D questionnaires.
RESULTS: 865 patients (64.7%) were recruited from Neurology department and 472 (35.3%) from Internal Medicine department. Those patients attended in Internal Medicine department were older and had more frequently hypertension, diabetes, heart failure, renal insufficiency and peripheral artery disease. Those patients attended in Neurology department had more commonly prior stroke. Overall, CHADS2 score was 3.2 ± 1.3, CHA2DS2-Vasc 4.8 ± 1.5 and HAS-BLED 2.0 ± 0.9. All scores were higher in those patients attended in Neurology department. Globally, 56.1% of patients were taking vitamin K antagonists, more commonly in Internal Medicine department. The adequate percent of time in therapeutic range was 47% (Rosendaal), without significant differences between groups. Satisfaction with oral anticoagulation was high in both groups, but higher in those attended in Neurology department, and higher in those individuals taking direct oral anticoagulants compared with vitamin K antagonists.
CONCLUSIONS: Although there were some differences in the clinical profile of patients with atrial fibrillation attended in Neurology or Internal Medicine departments, all of them had many comorbidities and a high thromboembolic risk. Despite INR control was poor, the most common oral anticoagulant used were vitamin K antagonists. Satisfaction related to oral anticoagulation was high.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28990646

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  3 in total

1.  Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies.

Authors:  Manuel Anguita; Mariano de la Figuera; Alejandro I Pérez Cabeza; Carmen Suarez Fernández
Journal:  Drugs Context       Date:  2019-10-09

2.  Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status.

Authors:  José Felipe Varona; José Miguel Seguí-Ripoll; Cristina Lozano-Duran; Luis Miguel Cuadrado-Gómez; Juan Bautista Montagud-Moncho; Antonio Ramos-Guerrero; José Carlos Mirete-Ferrer; Esther Donado; Javier García-Alegría
Journal:  Health Qual Life Outcomes       Date:  2020-12-11       Impact factor: 3.186

3.  Long-Term Anticoagulation in Secondary Ischemic Stroke Prevention: The Prospective Multicenter RESTAIC Registry.

Authors:  Raquel Gutiérrez-Zúñiga; Ricardo Rigual; Gabriel Torres-Iglesias; Sara Sánchez-Velasco; María Alonso de Leciñana; Jaime Masjuan; Rodrigo Álvarez Velasco; Inmaculada Navas; Laura Izquierdo-Esteban; José Fernández-Ferro; Jorge Rodríguez-Pardo; Gerardo Ruiz-Ares; Gustavo Zapata-Wainberg; Blanca Fuentes; Exuperio Díez-Tejedor
Journal:  Front Neurol       Date:  2020-10-19       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.